HuiD., BrueraE.Transdermal fentanyl: not ready for front line.J Palliat Care2009; 25(4): XX.
2.
WiffenP.J., McQuayH.J.Oral morphine for cancer pain.Cochrane Database Syst Rev2007; 17(4): CD003868.
3.
JadadA.R., BrowmanG.P.The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluation.JAMA1995; 274(23): 1870–1873.
4.
TassinariD., SartoriS., TamburiniE.Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials.J Palliat Care2009; 25(3): 172–180.
5.
TassinariD., SartoriS., TamburiniE.Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison with long-acting morphine: a meta-analysis and systematic review of the literature.J Palliat Med2008; 11(3): 492–501.
6.
BrueraE., PalmerJ.L., BosnjakS.Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study.J Clin Oncol2004; 22(1): 185–192.
7.
PaceM.C., PassavantiM.B., GrellaE.Buprenorphine in long-term control of chronic pain in cancer patients.Front Biosci2007; 12: 1291–1299.
8.
WirzS., WittmannM., SchenkM.Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl and transdermal buprenorphine.Eur J Pain2009; 13(7): 737–743.
9.
MercadanteS., PorzioG., FerreraP.Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.Eur J Pain2008; 12(8): 1040–1046.
